[WT1 peptide-based immunotherapy]

Haruo Sugiyama1

  • 1Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine.

The Wilms' tumor gene WT1 is overexpressed in leukemia and various types of solid cancers and its product is a tumor rejection antigen. A phase I clinical trials of WT1 peptide-based cancer immunotherapy were performed with good clinical response but with only skin reaction at the injection sites of WT1 vaccine. Thus, WT1-targeting immunotherapy should be promissing.

Related Concept Videos